Proprietary Medical Cannabis Products and Formulations Through - - PowerPoint PPT Presentation

CONFIDENTIAL

Proprietary Medical Cannabis Products and Formulations Through University Research and Development

OTC:CANQF

Richard Rusiniak, CEO * Paul Ramsay, President * Ross Eastley, CFO

Disclaimer

This presentation contains "forward-looking statements" as that term is defined in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this presentation which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, use of proceeds and the development, costs and results of current or future actions and opportunities in the sector. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, our ability to raise the additional funding we will need to continue to pursue our exploration and development program, and our ability to retain important members of our management team and attract other qualified personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this presentation are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

CONFIDENTIAL

Who we are…

Management team: Richard Rusiniak, CEO Paul Ramsay, President Ross Eastley, CFO

CONFIDENTIAL

Scientific team: 5 Scientists – at University of Waterloo 13 Scientists – at Western University We are a Health Product R&D Company Committed to utilizing cannabis and natural botanicals

Our Sci cientific team at t Univ iversity of

• f Waterloo

Fiv Five (5 (5) ) De Dedic icated Res esearchers in in can ancer res esearch

• Dr. Jonathan Blay

University of Waterloo

State-of-the-art cancer research laboratory in Canada's most innovative university

• Leading expert in discovery of novel cancer therapeutics and clinical use
• Focused team team of 5 with diverse skills and clinical backgrounds
• Perspective informed by longstanding interactions with medical schools
• Instrumentation allows studies from molecular to in vivo assessments
• Established track through to veterinary and human testing protocols

CONFIDENTIAL

Our ur Scie cientif ific ic tea eam at t Wes estern Uni niversit ity

Thir hirteen (13 13) Dedic icated Researchers in n Mental l He Healt alth research

Interface between Neurobiology, Psychology and Emotion

A 13-member team of multi-discipline departments working in the development of novel pharmacotherapies for mental health

• Dr. Steven Laviolette

Western University

CONFIDENTIAL

Wha hat we e do do…

❖ Work primarily in the science of cannabis – 13 years cannabis R&D expertise ❖ Utilize cannabis and other food grade botanical extracts ❖ Develop scientifically backed cannabis formulations with THC and CBD ❖ Formulate products as a better alternative for medical & recreational consumers today

CONFIDENTIAL

Our Products: Mentabinol™ - THC HC form

• rmulation

Mentrium™ - CB CBD form

• rmulation

Scientifically backed formulated medicine to help with:

• Anxiety
• Depression
• PTSD
• Schizophrenia

without negative side-effects

Sale les lice licence -ADC Bio Biomedical Co Corp.

100% subsidiary of CanaQuest Medical Corp.

Products for sale: le:

Precise dose, Enhanced bioavailability, GMP Pharmaceutical production process

Capsules

• Packaged in bottles
• 30 per bottle
• 60 per bottle
• Packaged in blister pack
• 2 per pack
• 10 per pack

Hard Pills

• Packaged in bottles
• 60 per bottle
• 100 per bottle
• Packaged in blister pack
• 2 per blister pack
• 10 per blister pack

Powder

• Packaged in 3-gram stick pack

Edibles - food and beverages

CanaQuest Medical Corp.

• Provides management and financial support for ADC BioMedical Corp

“ADC” (100% subsidiary of CanaQuest)

• Continuous university research and product development support
• Builds IP platform
• Secures THC and CBD supply, including financial arrangements on behalf
• f ADC
• Formalizes product formulation, production and packaging with Licensed

Producers “LPs” on behalf of ADC ADC BioMedical Corp. Health Canada medical cannabis sales license holder

• Sell directly to patients through e-commerce platform
• Distribute worldwide through LPs and international medical

cannabis distribution networks

• Import and export THC and CBD supply
• Export medical cannabis formulations internationally
• Control security, quality, inventory and delivery details

CONFIDENTIAL

Business Model

ADC BioMedical Corp.

100% subsidiary of CanaQuest Medical Corp.

ADC Biom

• medic

ical l - Part artners an and Col

• lla

laborators

CONFIDENTIAL

Licensed Producers / Processors Canada wide Locations: Quebec – Ontario – BC

• THC and CBD Suppliers
• Licenced Processing
• Packaging and
• Distribution

CONFIDENTIAL

The Sci cience of

• f Success by Dr. Steven Laviolette team Western University

Depression, Anxiety, and Schizophrenia related Symptoms Problem: Pre-clinical behavioral model of depression/anxiety, demonstrates neuronal, molecular and neuropsychiatric negative side effects from chronic exposure to THC Solution: Mentabinol™ - Due to THC co- administration with “BX”, the anhedonic (depression-like) effects are reversed.

CONFIDENTIAL

Memory Impairment Problem: Pre-clinical behavioral model of memory impairment (Novel Object Recognition) demonstrates chronic exposure to THC caused a significant object memory impairment Solution: Mentabinol™ Due to THC co- administration with “BX”, the memory impairment effect is completely blocked.

The Sci cience of

• f Success by Dr. Steven Laviolette team Western University

Hyperactive Activity Problem: Chronic THC exposure caused a significant dysregulation of the dopamine neurotransmitter system, shown by hyperactive activity rates in recordings of single dopamine neurons in the ventral tegmental area Solution: Mentabinol™ Due to THC co- administration with “BX”, the hyperactive activity effect is completely blocked.

CONFIDENTIAL

Gene Vulnerability Problem: Consistent with clinical genetic findings in human population showing that polymorphic abnormalities in the gene encoding Akt (protein kinase B) increase vulnerability to cannabis-induced neuropsychiatric side-effects Solution: Mentabinol™ Due to THC co- administration with “BX”, the gene vulnerability is completely blocked.

Th Thank you

• u

The Joy of Health

CONFIDENTIAL

Sci Scientific Reference – 4 pag pages

1. Algae - omega 3 oil and cannabis 2. Endocannabinoid system 3. DHA concentrated oil 4. Bioavailability

CONFIDENTIAL

Co Combining Alg lgae Oil il wit ith Ca Cannabis, ,

Creating Superior Health Products

CanaQuest recognized the need for DHA to enhance efficacy of cannabis

• Improving health of endocannabinoid system
• Supporting health of CB1 and CB2 receptors
• Boosting efficacy of cannabis treatment

CONFIDENTIAL

Co Combining Alg lgae Oil il wit ith Ca Cannabis, ,

Creating Superior Health Products

Research shows DHA made from essential fatty acids (EFAs) are critical to endocannabinoid system health

EFAs cannot be synthesized by our bodies but are needed for:

• Production of endocannabinoids and
• Supporting health of cannabinoid receptors

CONFIDENTIAL

CanaQuest algae oil extracts contain 22 fatty acids (66.3% Omega-3) 40%-50% DHA

The benefits of DHA extracted from algae oil include:

• Supports endocannabinoid system
• Improves memory
• Lowers risk of coronary heart disease and improvement in cholesterol

Supports results from studies:

• in cancer treatment,
• depression and
• attention-deficit hyperactivity disorder (ADHD)

DHA combined with BX and THC or CBD, including their many cannabinoids, enhances the efficacy significantly

Co Combining Alg lgae Oil il wit ith Ca Cannabis, ,

Crea eating ng Super perior

• r Heal

alth h Pr Produ ducts s

CONFIDENTIAL

Bio ioavaila labil ilit ity- mos

• st crit

critic ical fac actor

THC Bioavailability range and time of absorption

VAPING -10min Tincture – 10 min Smoking 10 min Edibles – 4 hrs Beverage - 6 hrs The more bioavailable a dose, the lower the quantity you need to experience the effects An intravenous dose is considered 100% bioavailable.

CONFIDENTIAL

U.S .S. . Can annabis is growth pr proje jectio ions

CONFIDENTIAL